Last reviewed · How we verify
ACYC — Competitive Intelligence Brief
marketed
Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
ACYC (ACYC) — Ligand Pharms. Acyc works by binding to a specific target in the body, although its exact mechanism is unknown.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ACYC TARGET | ACYC | Ligand Pharms | marketed | Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase | ||
| Aciclovir | Aciclovir | Assistance Publique Hopitaux De Marseille | marketed | Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). ACYC — Competitive Intelligence Brief. https://druglandscape.com/ci/acyc. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab